Pseudoporphyria complicating etretinate therapy.
Etretinate is recognized to have unwanted cutaneous effects such as dryness of the skin, pruritus and hair thinning. Photosensitivity has rarely been observed as an adverse reaction but we now describe a renal transplant recipient who developed lesions of cutaneous porphyria apparently as a result of etretinate prescribed to suppress cutaneous neoplasia.
McDonagh
A J
AJ
Harrington
C I
CI
D000328:Adult; D005050:Etretinate / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007642:Keratosis / Q000517:prevention & control; D016030:Kidney Transplantation; D008297:Male; D010787:Photosensitivity Disorders / Q000139:chemically induced / Q000150:complications; D011164:Porphyrias / Q000139:chemically induced*; D012871:Skin Diseases / Q000139:chemically induced*; D012878:Skin Neoplasms / Q000517:prevention & control
D005050:Etretinate